These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 29542872)

  • 1. An approach to shortening the timeframe between the emergence of new compounds on the drugs market and the availability of reference standards: The microscale syntheses of nitrazolam and clonazolam for use as reference materials, utilizing polymer-supported reagents.
    Dowling G; Kavanagh PV; Eckhardt HG; Twamley B; Hessman G; McLaughlin G; O'Brien J; Brandt SD
    Drug Test Anal; 2018 Mar; ():. PubMed ID: 29542872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonazolam Intoxication Case Report: Danger of Designer Benzodiazepines.
    Moore C; Hammers J; Marshall P
    Am J Forensic Med Pathol; 2022 Dec; 43(4):372-375. PubMed ID: 36281064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-fatal intoxications involving the novel benzodiazepine clonazolam: case series from the Emerging Drugs Network of Australia - Victoria project.
    Syrjanen R; Greene SL; Castle JW; Di Rago M; Hodgson SE; Abouchedid R; Graudins A; Schumann JL
    Clin Toxicol (Phila); 2023 Apr; 61(4):290-293. PubMed ID: 36988452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Designer Benzodiazepines: Another Class of New Psychoactive Substances.
    Moosmann B; Auwärter V
    Handb Exp Pharmacol; 2018; 252():383-410. PubMed ID: 30367253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro glucuronidation of designer benzodiazepines by human UDP-glucuronyltransferases.
    Pettersson Bergstrand M; Richter LHJ; Maurer HH; Wagmann L; Meyer MR
    Drug Test Anal; 2019 Jan; 11(1):45-50. PubMed ID: 29996009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urine Drug Screening in the Era of Designer Benzodiazepines: Comparison of Three Immunoassay Platforms, LC-QTOF-MS and LC-MS-MS.
    Puzyrenko A; Wang D; Schneider R; Wallace G; Schreiber S; Brandt K; Gunsolus IL
    J Anal Toxicol; 2022 Aug; 46(7):712-718. PubMed ID: 34557900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Development and Validation of a Novel Designer Benzodiazepines Panel by LC-MS-MS.
    Mastrovito RA; Papsun DM; Logan BK
    J Anal Toxicol; 2021 May; 45(5):423-428. PubMed ID: 33476376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic profiling of clonazolam in human liver microsomes and zebrafish models using liquid chromatography quadrupole Orbitrap mass spectrometry.
    Kong R; Zhao J; Zhai W; Chen Z; Yang S; Chen M; Lin J; Wu L; Liu W; Xiang P
    J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Feb; 1216():123583. PubMed ID: 36621072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines - an update comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam and nitrazolam.
    Moosmann B; Bisel P; Franz F; Huppertz LM; Auwärter V
    J Mass Spectrom; 2016 Nov; 51(11):1080-1089. PubMed ID: 27535017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of main human urinary metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxipam by nano-liquid chromatography-high-resolution mass spectrometry for drug testing purposes.
    Meyer MR; Bergstrand MP; Helander A; Beck O
    Anal Bioanal Chem; 2016 May; 408(13):3571-91. PubMed ID: 27071765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonazolam a new designer benzodiazepine intoxication confirmed by blood concentration.
    Sommerfeld-Klatta K; Łukasik-Głębocka M; Teżyk A; Panieński P; Żaba C; Zielińska-Psuja B
    Forensic Sci Int; 2020 May; 310():110237. PubMed ID: 32172178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fast and Sensitive Method for the Determination of 17 Designer Benzodiazepines in Hair by Liquid Chromatography-Tandem Mass Spectrometry.
    DeFreitas L; Fonseca Pego AM; Kronstrand R; Lendoiro E; de Castro-Ríos A; Concheiro M
    J Anal Toxicol; 2022 Oct; 46(8):852-859. PubMed ID: 35748814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood concentrations of new designer benzodiazepines in forensic cases.
    Høiseth G; Tuv SS; Karinen R
    Forensic Sci Int; 2016 Nov; 268():35-38. PubMed ID: 27685473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization and identification of eight designer benzodiazepine metabolites by incubation with human liver microsomes and analysis by a triple quadrupole mass spectrometer.
    El Balkhi S; Chaslot M; Picard N; Dulaurent S; Delage M; Mathieu O; Saint-Marcoux F
    Int J Legal Med; 2017 Jul; 131(4):979-988. PubMed ID: 28160051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designer benzodiazepine dependence and the difficulties of outpatient management; a case report.
    Reeves JJ; Brown AD; Collier BS
    J Addict Dis; 2024; 42(1):75-79. PubMed ID: 36112384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics.
    Moosmann B; Bisel P; Auwärter V
    Drug Test Anal; 2014; 6(7-8):757-63. PubMed ID: 24604775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An analytical strategy for designer benzodiazepines and Z-hypnotics determination in plasma samples using ultra-high performance liquid chromatography/tandem mass spectrometry after microextraction by packed sorbent.
    Ares-Fuentes AM; Lorenzo RA; Fernández P; Carro AM
    J Pharm Biomed Anal; 2021 Feb; 194():113779. PubMed ID: 33279303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective screening of synthetic cannabinoids, synthetic opioids and designer benzodiazepines in data files from forensic post mortem samples analysed by UHPLC-QTOF-MS from 2014 to 2018.
    Gundersen POM; Broecker S; Slørdal L; Spigset O; Josefsson M
    Forensic Sci Int; 2020 Jun; 311():110274. PubMed ID: 32302877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Designer Benzodiazepines: Comprehensive Review of Evolving Clinical and Adverse Effects.
    Edinoff AN; Nix CA; Odisho AS; Babin CP; Derouen AG; Lutfallah SC; Cornett EM; Murnane KS; Kaye AM; Kaye AD
    Neurol Int; 2022 Aug; 14(3):648-663. PubMed ID: 35997362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of Traditional and Designer Benzodiazepines in Urine through LC-MS/MS.
    Rossi B; Freni F; Carelli C; Moretti M; Galatone D; Vignali C; Morini L
    Curr Pharm Des; 2022; 28(32):2622-2638. PubMed ID: 36045516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.